Utah Medical Products, Inc. Announces Quarterly Dividend
Utah Medical Products (NASDAQ: UTMD) has announced a quarterly cash dividend of $0.305 per share of common stock. The dividend will be payable on July 3, 2025, to stockholders of record at the close of business on June 16, 2025. This represents a 1.7% increase compared to the dividend declared in the same quarter of the previous year. UTMD specializes in healthcare products for women and their babies, manufacturing and marketing specialty medical devices that are recognized globally across over 100 countries.
Utah Medical Products (NASDAQ: UTMD) ha annunciato un dividendo trimestrale in contanti di 0,305 $ per azione delle azioni ordinarie. Il dividendo sarà pagabile il 3 luglio 2025 agli azionisti registrati alla chiusura delle contrattazioni del 16 giugno 2025. Questo rappresenta un aumento dell'1,7% rispetto al dividendo dichiarato nello stesso trimestre dell'anno precedente. UTMD è specializzata in prodotti sanitari per donne e neonati, producendo e commercializzando dispositivi medici specializzati riconosciuti a livello globale in oltre 100 paesi.
Utah Medical Products (NASDAQ: UTMD) ha anunciado un dividendo trimestral en efectivo de 0,305 $ por acción de acciones comunes. El dividendo se pagará el 3 de julio de 2025 a los accionistas registrados al cierre del negocio el 16 de junio de 2025. Esto representa un aumento del 1,7% en comparación con el dividendo declarado en el mismo trimestre del año anterior. UTMD se especializa en productos de salud para mujeres y sus bebés, fabricando y comercializando dispositivos médicos especializados reconocidos mundialmente en más de 100 países.
Utah Medical Products (NASDAQ: UTMD)는 보통주 1주당 0.305달러의 분기별 현금 배당금을 발표했습니다. 배당금은 2025년 7월 3일에 지급되며, 2025년 6월 16일 영업 종료 시점에 주주명부에 등재된 주주들에게 지급됩니다. 이는 전년도 같은 분기에 선언된 배당금 대비 1.7% 증가한 수치입니다. UTMD는 여성과 아기를 위한 의료 제품을 전문으로 하며, 전 세계 100개국 이상에서 인정받는 특수 의료기기를 제조 및 판매하고 있습니다.
Utah Medical Products (NASDAQ : UTMD) a annoncé un dividende trimestriel en espèces de 0,305 $ par action d'actions ordinaires. Le dividende sera versé le 3 juillet 2025 aux actionnaires inscrits au registre à la clôture des opérations le 16 juin 2025. Cela représente une augmentation de 1,7 % par rapport au dividende déclaré au même trimestre de l'année précédente. UTMD se spécialise dans les produits de santé pour les femmes et leurs bébés, fabriquant et commercialisant des dispositifs médicaux spécialisés reconnus mondialement dans plus de 100 pays.
Utah Medical Products (NASDAQ: UTMD) hat eine vierteljährliche Bardividende von 0,305 $ pro Aktie der Stammaktien angekündigt. Die Dividende wird am 3. Juli 2025 an die Aktionäre ausgezahlt, die am Geschäftsschluss des 16. Juni 2025 im Aktienregister eingetragen sind. Dies stellt eine Steigerung von 1,7% im Vergleich zur Dividende im gleichen Quartal des Vorjahres dar. UTMD ist auf Gesundheitsprodukte für Frauen und ihre Babys spezialisiert und stellt spezielle medizinische Geräte her und vertreibt diese, die weltweit in über 100 Ländern anerkannt sind.
- Dividend increased by 1.7% year-over-year
- Consistent dividend payment demonstrates financial stability
- Global market presence in over 100 countries
- None.
SALT LAKE CITY, UT / ACCESS Newswire / May 6, 2025 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty and one-half cents ($.305) per share of common stock payable on July 3, 2025 to stockholders of record at the close of business on June 16, 2025. This is a
Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the standard for obtaining optimal long-term outcomes for their patients. For more information about Utah Medical Products, Inc., visit UTMD's website at www.utahmed.com.
Contact: Brian Koopman
(801) 566-1200
SOURCE: Utah Medical Products, Inc.
View the original press release on ACCESS Newswire